About the Company
We do not have any company description for Aptose Biosciences Inc. at the moment.
Exchange
OTC
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on Aptose Biosciences Inc.
Aptose Biosciences Inc. Announces Closing of $8 Million Public Offering
SAN DIEGO and TORONTO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company ...
Aptose Reports Second Quarter 2025 Results
Net loss for the quarter ended June 30, 2025 decreased by $0.2 million to $7.0 million, as compared to $7.3 million for the comparable period in 2024. Net loss for the six months ended June 30, 2025 ...
APTOSE BIOSCIENCES INC (APS.NE) - Yahoo Finance
Aptose and Hanmi Enter New Loan Agreement to Advance Development of Tuspetinib in Triplet Therapy for AML SAN DIEGO and TORONTO, June 20, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or ...
Aptose Biosciences Inc. Announces Pricing of $8 Million Public ... - Nasdaq
--Aptose Biosciences Inc., a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced the pricing of its ...
APS | Aptose Biosciences Inc. Profile | MarketWatch
Aptose Biosciences Inc. Aptose Biosciences, Inc. is a clinical-stage oncology company, which engages in the discovery, research, and development of anti-cancer therapies.
Aptose Biosciences, Inc.: Aptose Provides Corporate Updates
For further information, please contact Aptose Biosciences Inc. Susan Pietropaolo Corporate Communications & Investor Relations 201-923-2049 spietropaolo@aptose.com ...
Aptose Biosciences Inc. (NASDAQ:APTO) Q3 2023 Earnings Call Transcript
Aptose Biosciences Inc. beats earnings expectations. Reported EPS is $-1.76, expectations were $-2.16. Operator: Good afternoon. My name is Hope, and I will be your conference operator today.
Similar Companies
Loading the latest forecasts...